title: Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
authors.affiliation: Liver Transplant Unit, Virgen del Rocío Hospital, Seville, Spain. jmalamom@terra.es
authors.forename: J M A
authors.initials: JM
authors.lastname: Mártinez
authors.forename: L B
authors.initials: LB
authors.lastname: Pulido
authors.forename: C B
authors.initials: CB
authors.lastname: Bellido
authors.forename: D D
authors.initials: DD
authors.lastname: Usero
authors.forename: L T
authors.initials: LT
authors.lastname: Aguilar
authors.forename: J L G
authors.initials: JL
authors.lastname: Moreno
authors.forename: G S
authors.initials: GS
authors.lastname: Artacho
authors.forename: J S
authors.initials: JS
authors.lastname: Díez-Canedo
authors.forename: L M M
authors.initials: LM
authors.lastname: Gómez
authors.forename: M A G
authors.initials: MA
authors.lastname: Bravo
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000601:surgery; D000068338:Everolimus; D006084:Graft Rejection / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors*; D008113:Liver Neoplasms / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D012449:Safety; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
chemical_list: D007166:Immunosuppressive Agents; D047908:Intracellular Signaling Peptides and Proteins; D000068338:Everolimus; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus